<DOC>
	<DOCNO>NCT00005047</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know whether combination chemotherapy effective observation alone treat bladder cancer . PURPOSE : This randomized phase III trial study combination chemotherapy see well work compare observation alone treat patient bladder cancer .</brief_summary>
	<brief_title>4B951 , Combination Chemotherapy Treating Patients With Bladder Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare recurrence-free overall survival patient transitional cell carcinoma bladder p53 gene alteration treat methotrexate , vinblastine , doxorubicin , cisplatin vs observation alone . - Compare recurrence-free overall survival patient without p53 gene alteration treat observation alone . - Examine expression p53 gene , particularly RB , p21 , p16 , involve cell cycle regulation may involve response chemotherapy patient . - Correlate p53 mutational gene status p53 protein expression immunohistochemistry , outcome ( recurrence-free overall survival ) , response chemotherapy , expression key molecule p53-mediated apoptotic pathway patient treat regimen vs observation alone . OUTLINE : This randomize , multicenter study . Patients assign 1 2 treatment group base status p53 gene bladder tumor . - Group A ( p53 gene alteration , define great 10 % nuclear reactivity ) : Patients stratify accord age ( 65 vs 65 ) , stage ( P1 vs P2a v P2b ) , grade ( 1 2 v 3 4 ) , p21 status . Patients randomize 1 2 treatment arm within 10 week radical cystectomy bilateral pelvic lymphadenectomy within 2 week registration . - Arm I : Within 2 week randomization , patient receive methotrexate IV day 1 , 15 , 22 ; vinblastine IV day 2 , 15 , 22 ; doxorubicin IV cisplatin IV day 2 . Treatment repeat every 4 week 3 course absence disease progression unacceptable toxicity . - Arm II : Patients undergo observation recurrence receive adjuvant chemotherapy surgery . Patients eligible randomization decline randomize undergo observation recurrence . - Group B ( p53 gene normal , define less 10 % nuclear reactivity ) : Patients undergo observation recurrence receive adjuvant chemotherapy surgery . Patients follow every 6 month 5 year annually thereafter . PROJECTED ACCRUAL : A total 800 patient accrue study within 4.75 year .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven organ confine transitional cell carcinoma ( TCC ) bladder Must undergone radical cystectomy bilateral pelvic lymphadenectomy pathologic stage definitive cystectomy specimen P1 , P2a , P2b N0 , M0 TCC without squamous/glandular differentiation ( adenocarcinoma , squamous cell carcinoma , small cell carcinoma ) Margins must negative invasive situ TCC In situ TCC urethra ureter ( ) allow provided margin negative Clinical stage T1 , T2a , T2b base transurethral resection bladder tumor specimen P0 PIS N0 , M0 TCC allow Incidental pT2a ( Gleason score great 7 ) , pT2b ( Gleason score great 7 ) , pT2c ( Gleason score great 7 ) adenocarcinoma prostate allow No invasive tumor ureter ( ) urethra Must potentially curable disease Must register within 9 week surgery No metastatic disease physical exam chest xray CT scan chest Eligible randomization : p53 gene alteration present Randomization occur within 10 week surgery Those randomize receive ( MVAC ) methotrexate , vinblastine , doxorubicin , cisplatin begin MVAC within 12 week cystectomy No metastatic disease physical exam chest xray CT scan chest No prohibitive medical risk chemotherapy PATIENT CHARACTERISTICS : Age Any age Performance status ECOG 01 OR Karnofsky 70100 % Life expectancy Not specify Hematopoietic WBC least 4,000/mm^3 Platelet count least 150,000/mm^3 Hepatic SGOT SGPT great 2 time normal Alkaline phosphatase great 2 time normal Bilirubin normal Renal Creatinine great 1.8 mg/dL OR Creatinine clearance least 50 mL/min Blood urea nitrogen normal Cardiovascular No serious arrhythmias No congestive heart disease New York Heart Association class III IV status Randomization group : Ejection fraction must least 50 % MUGA scan clinical concern regard patient 's cardiac status Other No malignancy ( include synchronous papillary invasive upper urinary tract malignancy ) within past 5 year except incidental prostate cancer ( find cystectomy ) , basal cell squamous cell skin cancer , carcinoma situ cervix No concurrent advance medical illness psychologic disease No prohibitive medical risk chemotherapy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics No prior systemic chemotherapy bladder cancer At least 5 year since prior systemic chemotherapy Prior intravesical therapy allow Randomization group : Prior intravesical therapy allow administer prior cystectomy Endocrine therapy Not specify Radiotherapy No prior pelvic irradiation Surgery See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>stage I bladder cancer</keyword>
	<keyword>stage II bladder cancer</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
</DOC>